Showing 3901-3910 of 8217 results for "".
- Dr. Swanson: Dupilumab/Vaccines Question Has Been Answeredhttps://practicaldermatology.com/news/Dr-Swanson-Dupilumab-Vaccines-Question-Has-Been-Answered/2471166/The biggest remaining question about dupilumab has been answered by the allergy and immunology community, Practical Dermatology Associate Medical Editor Elizabeth (Lisa) Swanson, MD, FAAD, said at the Winter Clinical Hawaii 2025 meeting in Waikoloa Village, Hawaii. “The only realy question
- POETYK-PSO LTE: No New Safety Signals for Deucravacitinib at Five Yearshttps://practicaldermatology.com/news/poetyk-lte-no-new-safety-signals-for-deucravacitinib-at-five-years/2471170/Sotyktu (deucravacitinib) showed sustained efficacy and an acceptable safety profile over a period of 5 years in adults with moderate-to-severe plaque psoriasis, according to an announcement by Bristol Myers Squibb. Based on rec
- New Dupilumab Data for CSU to Be Presented at AAAAI Meetinghttps://practicaldermatology.com/news/New-Dupilumab-Data-CSU-Be-Presented-AAAAI-Meeting/2471105/New phase 3 data on dupilumab for chronic spontaneous urticaria (CSU) will be among 24 abstracts presented by Sanofi at the American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego, California, from February 28 to March 3. The dupilumab CSU data from the LIBER
- Analysis: AI Sensor Reduces Scratching in Atopic Dermatitis Patientshttps://practicaldermatology.com/news/ai-sensor-reduces-scratching-in-atopic-dermatitis/2471104/A wearable sensor utilizing artificial intelligence (AI) with haptic feedback significantly reduced nocturnal scratching in adults with mild atopic dermatitis, a new study reports. Researchers for the single-arm, two-stage cohort study recruited 10 adults (60% female; mean age, 36) with at
- Football Star OBJ to Raise Awareness of Seborrheic Dermatitis With Arcutishttps://practicaldermatology.com/news/Football-Star-OBJ-Raise-Awareness-Seborrheic-Dermatitis-With-Arcutis/2471099/NFL star Odell Beckham Jr. will help raise awareness of seborrheic dermatitis as part of a partnership with Arcutis Biotherapeutics, the company announced. “Seb derm is such a common condition, but like me, many people may have a hard time trying to figure out what it is and what can be do
- DELTA TEEN: Positive Results for Delgocitinib in Adolescent Chronic Hand Eczemahttps://practicaldermatology.com/news/delta-teen-positive-results-for-delgocitinib-in-adolescent-chronic-hand-eczema/2471096/Phase 3 data from the DELTA TEEN trial demonstrated that Anzupgo® (delgocitinib) cream achieved significant improvements in symptoms of moderate to severe chronic hand eczema (CHE) in adolescents aged 12–17, according to a news release from the manufacturer. The DELTA TEEN trial was a 16-w
- Study: Newer Biologics Do Not Increase MACE/VTE Risk in PsO/PsAhttps://practicaldermatology.com/news/Study-Newer-Biologics-Do-Not-Increase-MACE-VTE-Risk-PsO-PsA/2471065/A new emulated target trial analysis found no significant risk differences in major adverse cardiovascular events (MACE) or venous thromboembolic events (VTE) in patients with psoriasis or psoriatic arthritis treated with IL-17, IL-12/23, or IL-23 inhibitors vs those treated with TNF inhibitors.<
- Study: Higher Isotretinoin Doses Reduce Acne Relapse Riskhttps://practicaldermatology.com/news/study-higher-isotretinoin-doses-reduce-acne-relapse-risk/2470951/Results from a new cohort study show higher cumulative isotretinoin dosages are associated with lower rates of acne relapse and retreatment, and that daily dosing does not influence these outcomes for patients on conventional or high cumulative doses. Authors on the study analyzed data fro
- GHG Audit Shows Key Emission Sources in Dermatology Practicehttps://practicaldermatology.com/news/ghg-audit-shows-key-emission-sources-dermatology-practice/2470894/A new study has identified scope 3 emissions, particularly purchased goods and services, as the largest contributor to the carbon footprint of an outpatient dermatology clinic, accounting for 51.1% of total greenhouse gas (GHG) emissions. The research, conducted at a University of Pennsylv
- Analysis: FDA Approvals Highlight Disparities in Oncology Outcomes by Ancestryhttps://practicaldermatology.com/news/analysis-fda-approvals-highlight-disparities-oncology-outcomes-ancestry/2470889/Patients of African ancestry remain underrepresented in eligibility for biomarker-driven precision oncology therapies, according to a new study in JAMA Dermatology. The retrospective analysis of 59,433 patients with solid cancers looked at genetic sequencing data from MSK-IMPACT a